REVIEW

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

Minlin Jia^a,b, Keyi Jia^a,b, Lei Wang^a, Wei Li^a, Bin Chen^a, Yu Liu^a,b, Hao Wang^a,b, Sha Zhao^a, Yayi He^a,* Caicun Zhou^a,*

^a Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China
^b Medical School, Tongji University, Shanghai 200433, China

Received 23 September 2020; received in revised form 25 October 2020; accepted 3 November 2020

Abstract Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response (DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1 (PD-L1) and interact with signaling such as cyclic GMP–AMP synthase-stimulator of interferon genes (cGAS–STING) signaling. Here, we review the basic knowledge of DDR pathways, mechanisms of genomic instability induced by DDR

KEY WORDS DNA damage response; DNA repair; Immunotherapy;

Abbreviations: ATM, ataxia-telangiectasia mutated; ATR, ataxia telangiectasia and Rad3 related; BAP1, BRCA1-associated protein 1; BER, base excision repair; BRAF, v-RAF murine sarcoma viral oncogene homologue B; BRCA, breast cancer susceptibility gene; cGAS, cyclic GMP–AMP synthase; CHEK, cell-cycle checkpoint kinase; CHK1, checkpoint kinase 1; DAMP, damage-associated molecular patterns; DDR, DNA damage response; DR, direct repair; DSBs, double-strand breaks; GSK3β, glycogen synthase kinase 3β; HMGB1, high mobility group box-1; HRR, homologous recombination repair; ICI, immune checkpoint inhibitor; IFNγ, interferon gamma; IHC, immunohistochemistry; IRF1, interferon regulatory factor 1; JAK, Janus kinase; MAD1, mitotic arrest deficient-like 1; MGMT, O6-methylguanine methyltransferase; MLH1, MutL. homolog 1; MMR, mismatch repair; MNT, MAX network transcriptional repressor; MSH2/6, MutS protein homologue-2/6; MSI, microsatellite instability; MUTYH, MutY homolog; MyD88, myeloid differentiation factor 88; NEK1, NIMA-related kinase 1; NER, nucleotide excision repair; NGS, next generation sequencing; NHEJ, nonhomologous end-joining; NIMA, never-in-mitosis A; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PALB2, partner and localizer of BRCA2; PARP, poly-ADP ribose polymerase; PCR, polymerase chain reaction; PD-1, programmed death 1; PD-L1, programmed death ligand 1; PFS, progression-free survival; RAD51C, RAD51 homolog C; RB1, retinoblastoma 1; RPA, replication protein A; RSR, replication stress response; SCNAs, somatic copy number alterations; ssDNA, single-stranded DNA; STAT, signal transducer and activator of transcription; STING, stimulator of interferon genes; TBK1, TANK-binding kinase 1; TILs, tumor-infiltrating lymphocytes; TLR4, Toll-like receptor 4; TMB, tumor mutational burden; TME, tumor microenvironment; TP53, tumor protein P53; TRIF, Toll-interleukin 1 receptor domain-containing adaptor inducing INF-β; FDA, United State Food and Drug Administration; XRCC4, X-ray repair cross complementing protein 4.

*Corresponding authors.
E-mail addresses: 2250601@qq.com (Yayi He), caicunzhoudh@126.com (Caicun Zhou).
Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.01.003
2211-3835 © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Cancer is a main public health problem in the world with a high incidence of estimated 18.1 million new-diagnosed cases, and a mortality of 9.6 million deaths reported in 2018 global cancer statistics\(^1\). With the continuous improvement of early diagnosis and treatments, the rate of cancer related death decreased continuously since 1991, leading to a 29% overall decline through 2017\(^2\). Great success has been achieved in immune checkpoint inhibitor (ICI)-based immunotherapies\(^3\)-\(^4\). Two programmed death 1 (PD-1) blockades, nivolumab and pembrolizumab, were approved in 2014 by the United State Food and Drug Administration (U.S. FDA) for treating patients with metastatic melanoma who progressed after receiving ipilimumab, and patients with v-RAF murine sarcoma viral oncogene homologue B (BRAF)-mutated melanoma. In the combination of these PD-1 blockades, objective response was observed in 30%—40% of patients, and major responses were durable\(^5\). Besides, in patients with advanced solid tumors, an elegant study of Marabelle and colleagues\(^6\) found that objective response rate was 29% in the tissue tumor mutational burden (TMB)-high group when treated with pembrolizumab monotherapy. However, there were also some non-responders reported, and potential adverse events as well as increased cost were seen during immunotherapy\(^7\). These findings suggest a great need for exploring biomarkers and therapeutic strategies to treat cancers.

Genomic instability remains an enabling feature of cancer and promotes malignant transformation\(^7\). Hereditary cancer predisposition syndromes (such as Lynch syndrome) associated with genetic mutations of the core DNA repair genes are the initial evidence suggesting the importance of genome stability in tumorigenesis\(^8\). DNA damage response (DDR) pathways aim to protect cells against some acquired genome changes and monitor exogenous or endogenous DNA damage\(^9\). Cytotoxic agents targeting DDR pathways have been used as anti-cancer therapies. Many mechanisms of tumor cells’ resistance and sensitivity to cytotoxic radiotherapy and chemotherapy are controlled by DDR pathways. Herein, we review the basic knowledge of DDR pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR alterations on immune system, and the potential applications of DDR alterations as biomarkers and therapeutic targets in cancer immunotherapy.

2. Basis of DDR pathway

DNA integrity affects the transmission of genetic information. DNA damage may occur from either endogenous or exogenous sources, and DNA repair are required for maintaining genomic integrity\(^10,11\). Beyond direct repair (DR), multiple pathways compose the DDR system: base excision repair (BER), mismatch repair (MMR), nucleotide excision repair (NER), homologous recombination repair (HRR) and nonhomologous end-joining (NHEJ, Fig. 1)\(^12\).

Although some damages can be repaired by direct reversal mediated via proteins such as \(O^6\)-methylguanine methyltransferase (MGMT), most are subject to DNA repairs mediated by a series of protein-mediated catalytic events. In the BER pathway, DNA glycosylase can recognize a damage base, which mediates base removal, while polymerase, nuclease, and ligase repair the lesion\(^13\). The MMR system mainly detects mismatches as well as insertion or deletion loops, which induces a single-strand incision, followed by DNA repair through polymerase, nuclease, and ligase enzymes\(^14\). In the NER pathway, recognition of the helix-distorting lesions is mediated by two different mechanisms: one is transcription-coupled NER (specifically targeting transcription-blocked lesions), the other is global-genome NER. The NER system often excises a oligonucleotide with 22—30 bases to remove damage, which triggers a single-stranded DNA (ssDNA) production\(^15\). DNA polymerases as well as related factors would act upon it before ligase completes the repair\(^15\).

HRR and NHEJ are mechanisms used in double-strand breaks (DSBs). In HRR, sister-chromatid sequences are used as the template for DNA repair, which restricts HRR to S and G2. Several sub-pathways are involved in HRR\(^16\). Nevertheless, its initiation is always mediated by ssDNA generation, promoted by proteins such as MRE11A—RAD50—NBN (MRN) complex. Then the ssDNA executes strand invasion of an undamaged partner chromosome, before DNA synthesis ensues\(^16\). As for NHEJ, DSBs are detected by Ku70/80 proteins. This complex then binds to DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to activate it, which results in recruitment as well as activation of the end-processing enzymes, polymerases and ligase\(^17,18\).

3. Mechanisms of DDR pathway defects

Methods including genetic and epigenetic inactivation mediate deficiencies of DDR pathways. Germline or somatic mutations are important mechanisms in genetic inactivation at the level of DNA sequence. Germline alterations in DDR pathways associate with incidence of some hereditary syndromes prone to form cancer, such as hereditary nonpolyposis colorectal cancer (Lynch syndrome) caused by MMR-deficiency, as well as hereditary breast and ovarian cancer caused by defective HRR. Several less common syndromes including ataxia-telangiectasia, Fanconi anemia, xeroderma pigmentosum and MutY homolog (MUTYH)-associated polyposis need biallelic germline mutations to form full predisposition phenotype of cancer\(^19—21\).

Beyond these hereditary syndromes, in some sporadic cancers, DDR-related germline mutations were also detected in population-based studies. DDR-associated genes can also undergo somatic mutations at high frequency. A pan-cancer analysis in 17 tumor types identified somatic mutations among 72 key DDR genes, which were mutated in at least 1% samples in a...
given tumor and were presented in more than one type of cancer. Another study on biliary tract cancer demonstrated 63.5% of patients with germline or somatic inactivation in DDR genes such as ataxia-telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), breast cancer susceptibility gene 1/2 (BRCA1/2), mismatch repair genes MutL homolog 1 (MLH1) and MutS protein homologue-2/6 (MSH2/6), cell-cycle checkpoint kinase (CHEK), and BRCA1-associated protein 1 (BAP1). The most-characteristic epigenetic mechanism involved in the regulation of DDR pathways is DNA methylation. An analysis of DNA methylation identified 5%–10% of the promoter CpG islands (normally un-methylated) were methylated abnormally in human cancers, which led to the silencing of related genes at the transcriptional level. Promoter methylations cause loss of somatic function in DNA repair genes such as MGMT of the DR pathway, MLH1 of the MMR pathway, BRCA1 and RAD51 homolog C (RAD51C) of the HRR pathway. Promoter methylations of MGMT and MLH1 have been shown as the early events in the multistep tumorigenesis, as they were observed in premalignant polyps and the normal epithelium of colon that was adjacent to the tumor. Studies on breast, as well as ovarian cancers, demonstrated hypermethylation of BRCA1 and RAD51C was associated with HRR deficiency, resulting in tumor predisposition. However, impact of epigenetic inactivation of genes BRCA1 and RAD51C remains debated, since not all gene methylation appears marked effects at the expression level. In addition, epigenetic mechanisms involved in the regulation of DNA repair include histone modification, RNA-mediated targeting, and nucleosome remodeling. For example, depletion of TRRAP can impair the hyperacetylation of DNA damage related histone H4 as well as the accumulation of repair molecules at DSB sites, which leads to defective HRR.

4. Defective/downregulated DDR pathway allows genomic instability

Absence of specific DDR pathway may lead to consequences such as mutations or chromosomal rearrangements, promoting genomic instability and tumor progression. Multiple cellular processes may impair genetic stability. For example, the stalled, reversed and folded replication forks can cause deregulation of DNA replication, which may result in replication stress and trigger chromosomal rearrangements and the formation of DNA DSB. Telomere maintenance contributes to the prevention of genome instability, and chromosomal instability may be produced due to upcapping or erosion of telomere. Beyond DNA replication stress and telomere maintenance, processes including chromosome segregation, RNA processing and epigenetic mechanisms also relate to genome instability. The defects of RNA processing destabilize genomes mediated by forming mutagenic R-loop structure and altering gene expressions that are crucial in maintaining genome stability.

5. Tumor microenvironment (TME) regulates genomic stability via DDR pathways

TME is characterized by vascular abnormalities, hypoxia, as well as acidic pH, and the major components of it include tumor cells, many non-malignant cells (such as T cells, dendritic cells and tumor associated fibroblasts), extracellular matrix, and...
blood vessels. Through TME, tumor can affect pathways of DNA damage and repair correspondingly. Tumor progression is accompanied with multiple complex interactions between cancer cells and TME, and TME functions in malignant transformation via inhibiting DDR pathways. For example, hypoxia was observed to downregulate c-MYC, a proliferation-promoting transcription factor that bound to promoters of MMR genes Mlh1 and Mlh2, leading to decrease of Mlh1 and Mlh2 at the transcriptional level. Besides, hypoxia also increased the binding of inhibitory transcription factors (MAX network transcriptional repressor (MNT) and mitotic arrest deficient-like 1 (MAD1)) to promoters of Mlh1 and Mlh2 genes. Therefore, the expression of MMR genes was downregulated. In addition, MMR proteins also relate to apoptosis, indicating that TME can promote the survival of tumor cells indirectly mediated by inhibiting some DDR pathways. Moreover, BRCA1 and RAD51 genes in the HRR pathway are also associated with hypoxia, which may link to the increase of genomic instability. Thus, TME can negatively regulate genomic stability by repressing DDR pathways.

6. Impacts of DDR alterations on immune system in cancers

6.1. DDR deficiencies activate innate immune system through cyclic GMP–AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway

Before the recognition of adaptive immunity, innate immune system plays an important part in recruiting immune cells to tumors. Recent studies indicate the STING pathway as an important player in host innate immune system against cancer, which drives interferon (IFN) production and arouses T-cell responses. When exposed to DNA-damaging agents such as clinical chemotherapy (etoposide and camptothecin), STING pathway can be activated. Emerging evidence suggests micronuclei produced by BRCA2-inactivation can initiate a cGAS/STING-mediated interferon response. Enhanced IFN-related gene expression and higher abundance of tumor-infiltrating lymphocytes (TILs) were observed in DDR-
deficient breast cancers compared with DDR-proficient tumors. Upregulated TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) phosphorylation was also observed in BRCA1/2-deficient cancers.

6.2. DDR deficiencies improve tumor recognition of adaptive immune system

In adaptive immune responses, activation of specific T cells is essential in the interaction among MHC molecules displayed on the surface of antigen presenting cells, T cell receptor and costimulatory molecules expressed on the surface of naïve T cells. Accumulation of intratumoral T cells necessitates recognition of antigens (such as cancer testis-antigens, antigens from overexpressed oncogenes, and neoantigens). The quantity of tumor neoantigen is positively correlated with the number of non-synonymous mutations in a tumor, which varies in different development of cancer or across diverse cancers. Neoantigen hypothesis is that a non-synonymous mutation leads to the change of an amino acid, which produces a new peptide. Therefore, cancer cells with DDR-deficiency can be recognized as foreign cells by immune system (Fig. 2B).

6.3. Regulation of programmed death ligand 1 (PD-L1) responds to DNA damaging and repair signaling in tumor cells

DNA damage has been studied capable of inducing the expression of PD-L1 mRNA, thereby increasing the expression of PD-L1 in cell surface. This regulation depends on the activity of the transcription of ATM-ATR/checkpoint kinase 1 (CHK1) signaling, and defective DDR may link to greater PD-L1 upregulation induced by DSB. Defective BRCA or KU70/80 could significantly upregulate PD-L1 expression after radiation. HRR pathway requires BRCA2 to function in promoting the switch of RAD51 from replication protein A (RPA) on the ssDNA regions. Thus, BRCA2 deficiency would impair this switch ability, resulting in RPA accumulation at the DSB ends and continuous activation of ATR/CHK1 signal. Defective BRCA2 or KU70/80 could significantly upregulate PD-L1 expression after radiation.

6.4. Excessive DNA damage arouses immune responses by cell death signals

Apoptosis or mitotic catastrophe-induced cell death may occur mediated by excessive DNA damage in cancer cells. High mobility group box-1 (HMGB1) is released from dying cells, to
activate Toll-like receptor 4 (TLR4) pathway and increase myeloid differentiation factor 88 (MyD88)/Toll-interleukin 1 receptor domain-containing adaptor inducing INF-β (TRIF) signaling, which can stimulate immune activity. Multiple types of DNA damage can be caused by chemotherapy or radiotherapy, and DSBs are associated closely with cell death. Tumors with deficiency of NHEJ or HRR, may show higher sensitivity to chemotherapy or radiotherapy, and promote greater release of damage-associated molecular patterns (DAMPs) into TME after these treatments. For example, tumors with low expression of X-ray repair cross complementing protein 4 (XRCC4, a main component of the NHEJ pathway), might release more DAMPs after radiotherapy, with better therapeutic benefits. Although great immune activity is stimulated by DAMPs, the TLR4/MyD88/TRIF signaling mediated by HMGB1 could also upregulate PD-L1 expression in the neighboring surviving tumor cells. This process may inhibit immune activity to some extent after tumor receiving chemotherapy or radiotherapy.

6.5. Tumor aneuploidy and immune evasion

Genomic instability manifests as increased point mutation and chromosome instability. DDR pathway can also take a role in maintaining chromosome instability. For example, mitotic protein kinases, such as never-in-mitosis A (NIMA) in fungi, have been regarded to maintain genomic integrity. A component of DDR pathway named NIMA-related kinase 1 (NEK1) can maintain genomic integrity in mammalian ortholog. Research in NEK1-deficient cells showed faulty mitotic chromosome segregation, leading to aneuploidy. Inactivation of NEK1 could result in tumor formation without anchorage dependence. Besides, somatic copy number alterations (SCNAs) are also correlated with immune evasion, including reduced adaptive immune signaling, cytotoxic T cell activity and cytokine signaling. For example, based on TCGA dataset, a study identified more than 5000 tumors across 12 tumor types, and revealed high levels of SCNAs were correlated with decreased expression of cytotoxic immune cell markers. In a trial on metastatic melanoma patients, high burden of SCNAs in non-responders to PD-1 and activators of DDR pathways were associated with patients’ response to ICI immunotherapy.
Much attention has been drawn to the association between DDR alterations and response to ICI immunotherapy in various cancer types (Table 162 alterations and response to ICI immunotherapy in various cancer). The result of a heat map demonstrated there were more type (WT) tumors. Interestingly, with enriched BRCA1/2 mutations showed higher response to ICI therapy. The ORR was 5% in patients regardless of PD-L1 expression, while 12% ORR was shown in patients with BRCA1/2 mutations69. Patients with DNA polymerase epsilon (POLE)-mutated cancers also exhibit stronger response to ICIs. A study identified the association between patients’ response to PD-1 inhibitor and POLE-mutation in endometrioid endometrial cancers. The result of a heat map demonstrated there were more immune-related genes in POLE-mutated group than POLE-wild type (WT) tumors. Interestingly, POLE-mutated tumors also showed higher expression of immune checkpoint proteins (such as PD-L1) blockade was identified associated with reduced expression of immune-related genes60).

Point mutations of DDR pathways may also correlate with tumor immune-evasion. BAP1 protein, a tumor suppressor mentioned before, is closely associated with DDR through interactions with BRCA1. Figueiredo and colleagues suggested BAP1 loss in uveal melanomas could cause upregulation of regulatory T cells, which could inhibit the cytotoxicity of effector T cells. They further found regulatory immune markers CD74 and CD38 were upregulated in tumors with BAP1 loss. Thus, compounds inhibiting CD38 and/or CD74 may potentially become adjuvant therapies for immunotherapy. Thus, how to elicit immune-evasion of DDR alterations in cancer immunotherapy should be considered carefully.

7. Application of DDR alterations in cancer immunotherapy

7.1. Potential of DDR pathway alterations in predicting ICI response

Table 2 Combinations of DDR-targeted inhibitors with ICI immunotherapies.

| Clinical trial ID | Cancer type | DDR-targeted inhibitor | ICI | Phase |
|-------------------|-------------|------------------------|-----|-------|
| NCT04209686       | Advanced GAC| Olaparib               | Pembrolizumab | Phase II |
| NCT04052204       | SCCHN, prostate cancer | Talazoparib           | Avelumab      | Phase II |
| NCT04034927       | Ovarian, fallopian tube and peritoneal cancer | Olaparib            | Tremelimumab | Phase II |
| NCT03964532       | Breast cancer | Talazoparib           | Avelumab      | Phase I, phase II |
| NCT03950405       | SCLC        | Rucaparib             | Nivolumab     | Phase II |
| NCT03951415       | Endometrial cancer | Olaparib            | Durvalumab    | Phase II |
| NCT03851614       | Colorectal cancer, pancreatic adenocarcinoma, leiomyosarcoma | Olaparib             | Durvalumab    | Phase II |
| NCT03834519       | Prostatic neoplasms | Olaparib             | Pembrolizumab | Phase III |
| NCT03824704       | Solid tumors | Rucaparib             | Nivolumab     | Phase II |
| NCT03810105       | Prostate cancer | Olaparib            | Durvalumab    | Phase II |
| NCT03642132       | Ovarian cancer | Talazoparib         | Avelumab      | Phase III |
| NCT03639935       | Biliary tract cancer | Rucaparib         | Nivolumab     | Phase II |
| NCT03602859       | Ovarian cancer | Niraparib            | Dostarlimab   | Phase III |
| NCT03572478       | Prostate, endometrial cancer | Niraparib          | Dostarlimab   | Phase IIb |
| NCT03544125       | Metastatic triple negative breast cancer | Olaparib          | Durvalumab    | Phase I |
| NCT03522446       | Ovarian cancer | Rucaparib            | Nivolumab     | Phase III |
| NCT03404960       | Pancreatic adenocarcinoma | Niraparib       | Nivolumab     | Phase I, phase II |
| NCT03330405       | Solid tumors | Talazoparib         | Avelumab      | Phase II |
| NCT03167619       | Triple negative breast cancer | Olaparib        | Durvalumab    | Phase II |
| NCT03061188       | Euerent or refractory stage IV solid tumors | Veliparib       | Nivolumab     | Phase I |
| NCT02953457       | Ovarian, fallopian tube or primary peritoneal cancer | Olaparib       | Durvalumab    | Phase II |
| NCT02944396       | NSCLC       | Veliparib             | Nivolumab     | Phase I |
| NCT02849496       | Breast cancer | Olaparib            | Atezolizumab  | Phase II |
| NCT02660304       | Solid tumors | Pamiparib            | Tremelimumab | Phase I |
| NCT02657889       | Triple-negative breast cancer or ovarian cancer | Niraparib       | Pembrolizumab | Phase I, phase II |
| NCT02517275       | BRCA-deficient ovarian cancer | Olaparib       | Tremelimumab | Phase I, phase II |

DDR, DNA damage repair; GAS, gastric adenocarcinoma; ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; PD-1, programmed death 1; SCCHN, squamous cell carcinoma of the head and neck; SCLC, small cell lung cancer.
increased tumor immunogenicity. Teo and colleagues analyzed 34 DDR genes in several pathways. In patients with metastatic urothelial carcinoma receiving atezolizumab (anti-PDL1 antibody) or nivolumab (anti-PD-1 antibody), deleterious DDR alterations were related to longer survival. Recent studies suggested BAP1 might help to identify tumors that responded to cancer immunotherapy. In malignant mesothelioma, tumors with BAP1 mutations were distinctly correlated with an inflammatory TME, increased TILs and immune checkpoint activation. To date, ICI trials for mesothelioma do not consider status of genomic biomarkers. Thus, BAP1 mutations should be considered as potential biomarkers to predict patients’ response to ICIs in mesothelioma. Although many DDR genes were studied, few studies about genes in the NHEJ pathway were reported. Additional studies are required to explore the role of these genes in cancer immunotherapy.

Multiple defects in different DDR pathways may lead to higher genomic instability. Recently, Wang and colleagues prompted that co-mutations in DDR pathways might become a helpful biomarker in ICI immunotherapy. They mainly identified co-mutations in the HRR and MMR pathways (HRR-MMR) as well as HRR and BER pathways (HRR-BER). They collected data of whole-exome sequencing and mRNA expression across 29 tumors, with the observation of higher TMB and neoantigens in DDR-comutated groups. However, this study suggested that a single DDR pathway alteration could not predict higher TMB. They further investigated the response of cancer patients with co-mutations of DDR pathways to clinical ICIs, confirming the predictive role of co-mutations of DDR pathways in ICI immunotherapy.

However, not all diagnosed DDR-deficient patients respond to ICI immunotherapies. Interestingly, Touat and colleagues recently analyzed the mutational signatures in 10,294 gliomas. Although their results discovered MMR deficiency could be triggered by temozolomide, MMR-defected gliomas showed poor survival and low patients’ response to PD-1 inhibitors, with a lack of TIL abundance. Therefore, it remains a challenge to choose useful diagnostic assays of DDR deficiency. Take MMR testing as an example. Emerging study demonstrated that tumors with MMR deficiency determined by immunohistochemistry (IHC) or polymerase chain reaction (PCR)-based MSI may not necessarily responded to ICIs. In advanced prostate cancer, a study compared the association of MMR status determined by different assays. The results of MMR-mutated patients tested by IHC or PCR assay showed decreased OS, which was discordant compared with results based on next generation sequencing (NGS) testing. This study regarded NGS-based testing as an improved assay of MSI detection, but the challenge of cut-off definition was still maintained.

Another challenge occurs because somatic mutations have time heterogeneity, highlighting the limitation to define DDR status in cancers. It would help a lot if a novel strategy can be designed to detect DNA repair functions dynamically.

7.2. Combinations of DNA-damaging agents with ICIs

The strategy to combine DNA-damaging agents with ICIs may enhance genomic instability and immunotherapy activity. Tumor immunogenicity may be increased by the standard care of DNA-damaging chemotherapy as well as radiotherapy, mediated via mechanisms such as DNA damage with cytosolic dsDNA production and immunogenic induction of cell death with increased antigen presentation. Therefore, several clinical trials were developed to investigate the efficacy of combining chemotherapy and ICIs, and a significantly longer survival has been observed in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab co-administrated with chemotherapy in the first line. In addition, a phase I clinical trial in NSCLC patients showed a marked clinical benefit when pembrolizumab combined with radiation therapy.

A main limitation of DDR-targeted inhibitors is the development of acquired resistance. The significant correlation between DDR alterations and immune system in cancers suggests that combining DDR-targeted agents with ICI-based immunotherapies is very promising. Success of PD-1 inhibitor in tumors with MMR deficiency proves that neoantigen generation mediated by defective DDR can induce an immune response. But unlike MMR-defective malignancies, some tumors may not produce sufficient neoantigen burden to arouse immune response, and inhibiting DDR proteins may also generate insufficient neoantigens. In this case, interactions between DDR proteins and some immunomodulators are potential to stimulate immune activity against cancer.

Proteins of the poly-ADP ribose polymerase (PARP) family play crucial roles in various cellular processes including DNA repair, aspects of replication stress response (RSR), and chromatin modulation. As for DNA repair, PARP1 and PARP2 are important in the repair of DNA strand break through diverse DDR pathways, and cells with HRR defects are dependent on PARP activity for survival. Application of PARP inhibitors may help the formation of inflammatory TME (Fig. 4). For example, in murine ovarian tumors with BRCA1 deficiency, treatment of a PARP1 inhibitor talazoparib (BMN 673) can increase CD8+ lymphocyte infiltration as well as promote the production of IFNγ and tumor necrosis factor (TNF)-α. Its combination with ICIs could further promote the establishment of immune system with higher lymphocyte infiltration and IFNγ production. In addition, PARP inhibitors can also inactivate glycogen synthase kinase 3β (GSK3β) and enhance PD-L1 upregulation in a dose-dependent manner, therefore inhibiting T-cell activity (Fig. 4). PD-L1 blockade was found capable of re-sensitizing these tumor cells to T-cell killing. In tumor models treated with alazaparib, olaparib, and rucaparib, combining PARP inhibitor with anti-PD-L1 antibody resulted in greater antitumor activity than either agent alone. The presence of cyto-plasmic DNA can also activate the cGAS–STING pathway to enhance innate immunity and drive T-cell priming. Emerging clinical trials have studied the safety and clinical efficacy of the combination therapy of DDR-targeted inhibitors and ICIs, and published clinical trials suggested that these combinations could be used safely (Table 2).

However, there are also some challenges in this combination including agent choice, dose of DNA damaging compounds, combination schedule and toxicity. Different immunogenicity of
DNA-damaging agents and dose-related myelosuppressive effects suggest the combination scheme should be considered carefully. Several successful anti-tumor studies have shown that treatment of receiving chemotherapy for a period of time before its combination with ICIs is an optional method[95,96]. Besides, many single arm trials suggest only a modest anti-cancer activity. Randomized clinical trials are required to determine whether these combination efficacies are superior to treatment of receiving ICI alone[25,30].

Besides, combination of DDR inhibition and radiation can enhance inflammatory response. For example, inhibiting ATR in mice could potentiate type I IFN response induced by radiation, thereby increasing TILs[31]. Combining WEE1 inhibition and radiation could increase the killing of malignant cells by cytotoxic T lymphocytes in a granzyme B-dependent manner[32]. When adding anti-PD-L1 antibody to WEE1 inhibitor plus radiotherapy, increased survival was shown in mice with head and neck squamous cell carcinoma. Although preclinical studies about the combination of DNA-PK inhibition, ICIs and radiotherapy are lacking, clinical trials of this combination are already recruiting[99]. The use of DDR inhibition can increase the immunogenicity of radiation, and the use of ICIs can further negate immunosuppressive effects. Thus, this combination represents a promising therapeutic method. The combination of three drugs may make the interpretation of clinical findings more complicated; therefore, it is urgently to conduct more preclinical and clinical studies.

8. Conclusions and perspectives

DNA damage repair response of tumor cells has a very profound effect in creating inflammatory TME. Great progress has been made in understanding the potential correlations of DDR and immunity. Defective or downregulated DDR pathway allows genomic instability in the existence of exogenous or endogenous DNA damage, and tumor microenvironment also contributes to the regulation of genomic instability through DDR pathways. Alterations of DDR pathways can generate neoantigens promoted by degradation of abnormal proteins due to mutations in the open reading frames. MMR deficiency, defective DNA replication, as well as endogenous oxidative DNA damage may contribute to these mutations. When exposed to chemotherapy and/or radiotherapy, DDR signaling is activated by DSBs. Activation of ATM-ATR/CHK1 can result in the upregulation of PD-L1 in tumor cells. DNA fragments may also be generated from cells with DSBs, which can be recognized by cGAS and activate the STING pathway. Excessive DNA damage could make cancer cells die, inducing DAMP release and arousing immune response. Thus, DDR pathways and their alterations have strong application prospects in cancer immunotherapy.

Some proteins with DDR deficiency represent potential biomarkers for cancer immunotherapy in different types of cancers. Besides, interactions between DDR pathway and TME make it tempting to combine DDR-related therapies and immunotherapy to treat cancer. Given that explaining the efficacy of the combined strategy (DDR inhibitor/ICI immunotherapy) is complex, some biomarkers are being explored to predict patients’ response. For example, a NanoString-based method was developed as a predictive biomarker through detecting expression of interferon genes[100]. In addition, preclinical immunocompetent models are also needed to evaluate the efficacy of the combination between DDR inhibitors and immunotherapies. Moreover, novel therapies have also been developed. For example, the manganese-based nanoactivator [doxorubicin (DOX)-loaded and phospholipid (PL)-coated hybrid nanoparticles] can optimize cancer immunotherapy through inducing DNA damage and increasing innate immunity[101]. Thus, developing novel therapeutic strategies based on DNA damage and repair may be very potential for cancer immunotherapy. Meanwhile, it is also challenging to seek ways of potentiating the immune-promotive impacts of DDR pathways while reducing immune-suppressive effects. Inhibiting immune-suppressive effects through flexibly using adjuvant therapies for immunotherapy in DDR-altered tumors, or enhancing immunogenicity through using DDR inhibitors may represent promising therapeutic approaches against cancers.

Acknowledgments

This study was supported in part by a grant from National Natural Science Foundation of China (81802255), Shanghai Pujiang Program (17PJ0036, China) and a grant from Shanghai Municipal Commission of Health and Family Planning Program (20174Y0131, China), National Key Research & Development Project (2016YFC0902300, China), major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC (16CR1001A, China), “Dream Tutor” Outstanding Young Talents Program (fkyq1901, China), key disciplines of Shanghai Pulmonary Hospital (2017ZZ0012, China), grant of Shanghai Science and Technology Commission (16JC1405900, China).

Author contributions

Minlin Jiang contributed significantly to analysis and manuscript preparation. Keyi Jia and Lei Wang provided suggestions for the improvement of manuscript. Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao contributed to the correction of the manuscript. Minlin Jiang, Yayi He and Caicun Zhou contributed to the conception of the study. Yayi He and Caicun Zhou helped perform the analysis with constructive discussions.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Fray B, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
3. Chen X, Fan X, Zhang W, Guo H, Cheng S, He Q, et al. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharmacol Sin 2020;41:723–33.
4. He Y, Yu H, Rozeboom L, Briedt C, Ellis K, Dziedziszkowicz R, et al. LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes. J Thorac Oncol 2017;12:814–23.
5. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:1270–1.
6. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020;21:1353–65.

7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–74.

8. Li SKH, Martin A. Mismatch repair and colon cancer: mechanisms and therapies explored. *Trends Mol Med* 2016;22:274–89.

9. Cleary JM, Aguirre AJ, Shapiro GI, D’Andrea AD. Biomarker-guided development of DNA repair inhibitors. *Mol Cell* 2020;78:1070–85.

10. Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. *Lancet Gastroenterol Hepatol* 2016;1:207–16.

11. Suh WK, Tafuri A, Berg-Brown NN, Shahinian A, Pyte S, Duncan GS, et al. The inductive costimulator plays the major immunostimulatory role in humoral immune responses in the absence of CD28. *J Immunol* 2004;172:5917–23.

12. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoadjuvant long, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. *Oncoarget* 2016;7:13587–98.

13. David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. *Nature* 2007;447:941–50.

14. Jiriný J. The multifaceted mismatch-repair system. *Nat Rev Mol Cell Biol* 2006;7:335–46.

15. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. *Nature* 2001;411:366–74.

16. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. *Annu Rev Biochem* 2008;77:229–57.

17. Lieber MR. The mechanism of human nonhomologous end joining. *J Biol Chem* 2008;283:1–5.

18. Warren AJ. DNA-repair enzyme turns to translation. *Nature* 2020;579:198–9.

19. Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. Risk of prostate cancer associated with familial and hereditary cancer susceptibility alleles. *Eur J Cancer* 2011;47:1807–13.

20. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. *The xeroderma pigmentosum paradigm*. *Arch Dermatol* 1994;130:1018–21.

21. Renwick A, Thompson D, Seal S, Kelly P, Chagati T, Ahmed M, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet* 2006;38:873–5.

22. Das S, Campphausen K, Shankavaram U. Pan-cancer analysis of potential synthetic lethal drug targets specific to alterations in DNA damage response. *Front Oncol* 2019;9:1136.

23. Chae H, Kim D, Yoo C, Kim KP, Jeong HJ, Chang HM, et al. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. *Eur J Cancer* 2019;120:31–9.

24. Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. *Nat Rev Cancer* 2011;11:726–34.

25. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. *Nat Genet* 2017;49:1476–86.

26. Tabano S, Azzollini J, Pesenti C, Lovati S, Costanza J, Fontana L, et al. Analysis of BRCA1 and RAD51C promoter methylation in Italian families at high-risk of breast and ovarian cancer. *Cancers* 2020;12:910.
Alterations of DNA damage response pathway for cancer immunotherapy

50. Sato H, Niimi A, Yasuhara T, Permuta TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 2017;8:1751.

51. Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 2018;128:3926–40.

52. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 2017;19:1189–201.

53. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Cirollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050–9.

54. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010;31:955–60.

55. Takada Y, Someya M, Matsumoto Y, Satoh M, Nakata K, Hori M, et al. Influence of Kui86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy. Med Mol Morphol 2016;49:210–6.

56. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Heturin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLIR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;100:296–304.

57. Chen Y, Chen CF, Chiang HC, Pena M, Polci R, Wei RL, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 2018;128:3926–40.

58. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Heturin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLIR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;100:296–304.

59. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017;355:eaaf8399.

60. Koh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 2017;9:eaaq3560.

61. Figuieredo CR, Kalirai H, Sacco JJ, Azavedo RA, Dukworth A, Slupsky JR, et al. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. J Pathol 2020;250:290–299.

62. Rereadon DA, Brandes AA, Omuoro A, Mulholland P, Lim M, Wick A, et al. Effect of NIVOLAM plus bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1033–1040.

63. Aiello MM, Vigneri PG, Bruzzi P, Verderame F, Paratore S, Vendetti FP, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 2020;580:517–23.

64. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13.

65. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Arcangelis F, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res 2018;78:6486–96.

66. Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 2018;128:5185.

67. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 2018;128:5185.

68. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–19.

69. De Bono JS, Goh JCH, Ojamaa K, Rodriguez JMP, Drake CG, Holmes CJ. KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2018;36:abs5007.

70. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damares L, Lane K, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 2016;126:2334–40.

71. Colebatch A, Hitchins M, Williams R, Meagher A, Hawkins NJ, Ward RL. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer 2006;95:1239–43.

72. Vidotto T, Neresian S, Graham C, Siemens DR, Koti M. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. J Immunother Cancer 2019;7:148.

73. Teo MY, Seier K, Ostrovnyaya I, Regazzi AM, Kania BE, Moram MM, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 2018;36:1685–94.

74. Ladanyi M, Vega FS, Zauderer M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med 2019;11:18.

75. Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med 2019;11:18.

76. Tubb A, Nussenzweig A. Endogenous DNA damage as a source of genomic instability in cancer. Cell 2017;168:644–56.

77. Wang ZI, Zhao J, Wang QQ, Zhang F, Zhang ZM, Zhang F, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res 2018;78:6486–96.

78. Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 2018;128:5185.

79. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 2020;580:517–23.

80. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13.

81. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Arcangelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92.

82. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017;18:895–903.

83. Mowu KW, D’Andrea AD. DNA repair deficiency and immunotherapy response. J Clin Oncol 2018;36:1710–3.

84. Forment JV, O’Connor MJ. Targeting the replication stress response to improve immunotherapy. J Immunother Cancer 2017;5:1257.

85. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017;355:1152–8.

86. Zhang BY, Lyu JF, Yang EJ, Liu YF, Wu CJ, Pardeshi L, et al. Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. Acta Pharmacol Sin 2020;41:615–27.

87. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, et al. Combination of DNA damaging agents with PARP inhibitors to enhance antitumor activity in BRCA1-deficient ovarian cancer. Cancer Immunol Res 2015;3:1257–68.

88. Huang J, Wang L, Cong ZY, Amozzag Z, Kiner E, Xing DY, et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in...
a Brca1−/− murine model of ovarian cancer. Biochem Biophys Res Commun 2015;463:551–6.
89. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23:3711–20.
90. Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS−STING, an important pathway in cancer immunotherapy. J Hematol Oncol 2020;13:81.
91. Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 2019;9:722–37.
92. Brown JS, Sundar R, Lopez J. Combining DNA damaging therapies with immunotherapy: more haste, less speed. Br J Cancer 2018;118:312–24.
93. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013;8:e61895.
94. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. IpiLumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046–54.
95. Konstantinopoulos PA, Waggoner S, Vidal GA, Mitra M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019;5:1141–9.
96. Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 2019;5:1132–40.
97. Dillon MT, Berghoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin E, et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin Cancer Res 2019;25:3392–403.
98. Patil P, Sun L, Robbins Y, Clavijo PE, Friedman J, Silvin C, et al. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. OncoImmunology 2019;8:e1638207.
99. McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer 2020;20:203–17.
100. Farkkila A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochpurakkal B, et al. Immunogenic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun 2020;11:1459.
101. Hou L, Tian CY, Yan YS, Zhang LW, Zhang HJ, Zhang ZZ. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity. ACS Nano 2020;14:3927–40.